UNSPSC 51432702: Zabicipril

This classification denotes an ace inhibitor with the molecular formula C23H32N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 475035SS4C, chemically known as (3s)-2-((2s)-n-((1s)-1-carboxy-3-phenylpropyl)alanyl)-2-azabicyclo(2.2.2)octane-3-carboxylic acid, 1-ethyl ester but generally known as zabicipril, which bears US NIH Compound Identifier 71262. European Medicines Agency schedules Zabicipril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00125MIG.

UNSPSC 51432702 Zabicipril, a Commodity code, covers emergency and critical-care pharmaceuticals supplied to state and local health systems, fire rescue services, and state health agencies. Recent solicitations show state and local governments procuring branded and generic medications for emergency medical services, hospital formularies, and pharmacy benefit programs—not the specific active pharmaceutical ingredient alone, but complete finished-goods medications for immediate clinical deployment. The code appears in fire rescue service solicitations for Advanced Life Support medications, in cooperative purchasing arrangements for multi-source generic pharmaceuticals and over-the-counter products distributed across state facility networks, and in state health commission procurement for direct-to-manufacturer pharmacy initiatives. Issuing bodies include city purchasing departments (fire rescue), state health agencies, multistate cooperative purchasing alliances, and health benefit administrators.

Activity spans Florida, Texas, Minnesota, and Oregon, with the most recent solicitations originating from city-level emergency services procurement and state-level health commission and cooperative purchasing initiatives. The City of Tampa's Purchasing Department issued an IFB on April 24, 2026 (response due April 8, 2026) for Advanced Life Support Medications including Labetalol, Epinephrine, Adenosine, and Diltiazem vials for Tampa Fire Rescue, estimated at $40,000 with a one-year term and renewal options, under a Small Local Business Enterprise sheltered market designation allowing a 5 percent bid discount. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued an RFP on January 20, 2026 (response due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities in Minnesota and Oregon, with awards effective July 1, 2026 and a two-year term. The Texas Health and Human Services Commission issued an RFI on April 3, 2026 for vendor capabilities regarding direct-to-manufacturer prescription programs under its Therapeutic Pharmacy Initiative, seeking to establish direct contracting relationships outside traditional pharmacy benefit manager and wholesaler channels.